Booster Vaccination With Further Live Attenuated Measles Vaccine

James W. Bass; Scott B. Halstead; Gerald W. Fischer; John K. Podgore; William R. Pearl; Manuel Schydlower; Robert A. Wiebe; Frederick M. Ching

doi:10.1001/jama.1976.03260270017018

Booster Vaccination With Further Live Attenuated Measles Vaccine

James W. Bass, Scott B. Halstead, Gerald W. Fischer, John K. Podgore, William R. Pearl, Manuel Schydlower, Robert A. Wiebe, Frederick M. Ching

Research output: Contribution to journal › Article › peer-review

5 Scopus citations

Abstract

Revaccination with live attenuated measles vaccine was evaluated in a large group of children to determine (1) if protective antibody to measles infection could be augmented and (2) after what interval will the revaccination yield optimal results. The rate of decline in measles hemagglutination-inhibition (HI) antibody was observed to be directly related to the time interval since the previous vaccination, and individuals with declining titers became increasingly responsive to revaccination with a maximal response approximately four to six years after previous vaccination. Six-month follow-up studies demonstrated sustained elevations in measles HI antibody titers. Measles-neutralizing antibody showed less tendency to sustain a titer increase after revaccination. These observations suggest that revaccination with live, further attenuated measles vaccine is safe and may augment immunity.

Original language	English
Pages (from-to)	31-34
Number of pages	4
Journal	JAMA: The Journal of the American Medical Association
Volume	235
Issue number	1
DOIs	https://doi.org/10.1001/jama.1976.03260270017018
State	Published - 5 Jan 1976

Access to Document

10.1001/jama.1976.03260270017018

Cite this

@article{35cda4eb7fe74b68bbca78a4d3151fa2,

title = "Booster Vaccination With Further Live Attenuated Measles Vaccine",

abstract = "Revaccination with live attenuated measles vaccine was evaluated in a large group of children to determine (1) if protective antibody to measles infection could be augmented and (2) after what interval will the revaccination yield optimal results. The rate of decline in measles hemagglutination-inhibition (HI) antibody was observed to be directly related to the time interval since the previous vaccination, and individuals with declining titers became increasingly responsive to revaccination with a maximal response approximately four to six years after previous vaccination. Six-month follow-up studies demonstrated sustained elevations in measles HI antibody titers. Measles-neutralizing antibody showed less tendency to sustain a titer increase after revaccination. These observations suggest that revaccination with live, further attenuated measles vaccine is safe and may augment immunity.",

author = "Bass, {James W.} and Halstead, {Scott B.} and Fischer, {Gerald W.} and Podgore, {John K.} and Pearl, {William R.} and Manuel Schydlower and Wiebe, {Robert A.} and Ching, {Frederick M.}",

year = "1976",

month = jan,

day = "5",

doi = "10.1001/jama.1976.03260270017018",

language = "English",

volume = "235",

pages = "31--34",

journal = "Journal of the American Medical Association",

issn = "0098-7484",

publisher = "American Medical Association",

number = "1",

}

TY - JOUR

T1 - Booster Vaccination With Further Live Attenuated Measles Vaccine

AU - Bass, James W.

AU - Halstead, Scott B.

AU - Fischer, Gerald W.

AU - Podgore, John K.

AU - Pearl, William R.

AU - Schydlower, Manuel

AU - Wiebe, Robert A.

AU - Ching, Frederick M.

PY - 1976/1/5

Y1 - 1976/1/5

N2 - Revaccination with live attenuated measles vaccine was evaluated in a large group of children to determine (1) if protective antibody to measles infection could be augmented and (2) after what interval will the revaccination yield optimal results. The rate of decline in measles hemagglutination-inhibition (HI) antibody was observed to be directly related to the time interval since the previous vaccination, and individuals with declining titers became increasingly responsive to revaccination with a maximal response approximately four to six years after previous vaccination. Six-month follow-up studies demonstrated sustained elevations in measles HI antibody titers. Measles-neutralizing antibody showed less tendency to sustain a titer increase after revaccination. These observations suggest that revaccination with live, further attenuated measles vaccine is safe and may augment immunity.

AB - Revaccination with live attenuated measles vaccine was evaluated in a large group of children to determine (1) if protective antibody to measles infection could be augmented and (2) after what interval will the revaccination yield optimal results. The rate of decline in measles hemagglutination-inhibition (HI) antibody was observed to be directly related to the time interval since the previous vaccination, and individuals with declining titers became increasingly responsive to revaccination with a maximal response approximately four to six years after previous vaccination. Six-month follow-up studies demonstrated sustained elevations in measles HI antibody titers. Measles-neutralizing antibody showed less tendency to sustain a titer increase after revaccination. These observations suggest that revaccination with live, further attenuated measles vaccine is safe and may augment immunity.

UR - http://www.scopus.com/inward/record.url?scp=0017298584&partnerID=8YFLogxK

U2 - 10.1001/jama.1976.03260270017018

DO - 10.1001/jama.1976.03260270017018

M3 - Article

C2 - 945997

AN - SCOPUS:0017298584

SN - 0098-7484

VL - 235

SP - 31

EP - 34

JO - Journal of the American Medical Association

JF - Journal of the American Medical Association

IS - 1

ER -

Booster Vaccination With Further Live Attenuated Measles Vaccine

Abstract

Access to Document

Other files and links

Fingerprint

Cite this